#transthyretin amyloidosis market share

[neha24blog]

Transthyretin Amyloidosis Treatment Market Segment Analysis By Type, Therapy, Disease Type, Distribution Channel, Region And Forecast Till 2030: Grand View Research Inc.

San Francisco, 24 Aug 2023: The Report Transthyretin Amyloidosis Treatment Market Size, Share & Trends Analysis Report By Type (ATTR-PN, ATTR-CM), By Therapy, By Disease Type, By Distribution Channel, By Region, And Segment Forecasts, 2022 – 2030 The global transthyretin amyloidosis treatment market size is expected to reach USD 9.17 billion by 2030, according to a new report by Grand View…

[ketshubhra]

Transthyretin (TTR) Amyloidosis Market | by Disease Type, Treatment, Gender, End User, and Region

Industry Research Report – Transthyretin (TTR) Amyloidosis Market forecast till 2023, is latest research report published by MRFR. The Global TTR Amyloidosis Market is segmented on the basis of treatment, gender, end-user, disease type, and Region.

Transthyretin (TTR) Amyloidosis Market Overview

The Transthyretin (TTR) amyloidosis market is likely to register a robust growth over the forecast period. Transthyretin (TTR) amyloidosis is a health condition characterized by anomalous deposits of a protein named amyloid (amyloidosis) in a person's tissues and organs. It usually affects autonomic neuropathy or peripheral neuropathic system and cardiac system. Amyloidosis symptoms are often ambiguous having similarity to symptoms caused by other conditions. The symptoms vary based on the location and type of the amyloid deposits. Primarily, three major types of transthyretin amyloidosis have been identified. The neuropathic type of transthyretin amyloidosis affects the autonomic and peripheral nervous systems, resulting in trouble controlling bodily functions and peripheral neuropathy. The leptomeningeal type of transthyretin amyloidosis mostly affects the central nervous system. The cardiac type of Transthyretin (TTR) amyloidosis puts patients at the risk of orthostatic hypertension, cardiomegaly, and arrhythmia.

Get a FREE Sample with Complete TOC By considering the COVID-19 impact on market @ https://www.marketresearchfuture.com/sample_request/6155

The surging African American population, increasing number of ATTR therapeutic drug launches, increasing average income of individuals, and growing healthcare awareness among people serves as key factors for driving the Transthyretin (TTR) amyloidosis market growth.

However, progress of the market can be restricted by strict governing policies, incorrect diagnosis of TTR ailments, restraints on clinical trials, and high cost of TTR drugs. Unavailability of advanced diagnostic methods in the middle-income nations and lack of knowledge about Transthyretin amyloidosis acts as major challenges to the market.

Transthyretin (TTR) Amyloidosis Market Segmentation

The worldwide Transthyretin (TTR) amyloidosis market has been segmented based on treatment, gender, end-user, and disease type. Based on treatment, the market has been segmented into organ transplantation, RNAi therapy, small molecules treatment, and others. Small molecules treatment has been sub-segmented as diflunisal and tafamidis. Based on gender, the market has been segmented into male and female. Based on end-user, the market has been segmented into ambulatory surgical centers, hospitals and clinics, and others. Based on disease type, the market has been segmented into Transthyretin (TTR) familial amyloid polyneuropathy, Transthyretin (TTR) familial amyloid cardiomyopathy, and others.

Transthyretin (TTR) Amyloidosis Market Regional Analysis

The Americas hold the largest market share for Transthyretin (TTR) amyloidosis. The growth is owing to the rising occurrence of amyloidosis among adults and older population and increasing elderly population. For instance, a report published by ASCO Journal in 2016 stated that almost 4,000 people suffered from amyloidosis each year in the United States. Additionally, increasing government funding, technologically advanced diagnostic equipment, and surging research initiatives in advanced medical treatment options are likely to drive the market. The existence of leading pharmaceutical brands such as Merck and Pfizer also boost the market in this region.

Europe represents the second largest share in the global Transthyretin (TTR) amyloidosis market. The Europe market has been anticipated to grow remarkably over the forecast period. The growth is owing to soaring healthcare expenditure, availability of progressive treatment facilities, amplifying demand for improved healthcare infrastructure collectively with government initiatives for healthcare reform. In the U.K., almost 60 new cases of Transthyretin (TTR) amyloidosis are reported every year. Furthermore, increased affordability coupled with well-established medical device manufacturers accelerate the market to a great extent. However, increasing incidences of wrong diagnosis and the inefficiency of treatment procedures are likely to restrict the growth in the Europe market.

Asia Pacific market has been fast expanding owing to rising aged population. Moreover, increasing patient pool, government initiatives to enhance the healthcare facility, availability of favorable insurance reimbursement policies, and a rapid adoption of advanced technology are likely to stimulate the Transthyretin (TTR) amyloidosis market.

The Middle East and Africa market has been anticipated to register least growth owing to limited access to treatment facilities and lack of health awareness. In the Middle East, Saudi Arabia and the United Arab Emirates are the largest markets. The market growth has been attributed to the easy accessibility of specialty care centers and growth of healthcare industry. However, the market is expected to witness steady development due to the genetical predisposition of Africans for transthyretin amyloidosis and administrative initiatives to excel the quality of healthcare in the region.

Transthyretin (TTR) Amyloidosis Market Key Players

The global Transthyretin (TTR) amyloidosis market has been dominated by key players such as Pfizer, Alnylam Pharmaceuticals, Ionis Pharmaceuticals Inc., Arcturus Therapeutics, Corino Therapeutics Inc, and Proclara Bioscience.

Obtain Premium Research Report Details, Considering the impact of COVID-19 @ https://www.marketresearchfuture.com/reports/transthyretin-amyloidosis-market-6155 

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:

Market Research Future

+1 646 845 9312

Email: sales@marketresearchfuture.com

NOTE: Our team of researchers are studying Covid-19 and its impact on various industry verticals and wherever required we will be considering covid-19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

[apurvasstuff]

Global Transthyretin Amyloidosis Treatment Market–Analysis and Demand with Forecast Overview to 2029

Published Date:December 2020

Robust pipeline of transthyretin amyloidosis treatment drugs is one of the major factors that is expected to propel growth of the market over the forecast period.

The global transthyretin amyloidosis treatment market accounted for US$ 40.5 million in 2019 and is anticipated to register a CAGR of 58.7%.

The report "Global Transthyretin Amyloidosis Treatment Market, By Drug (Inostersen, Partisiran, Tafamidis, and Others), By Indication (Wild Type ATTR Amyloidosis, and Hereditary ATTR Amyloidosis), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy), and By Region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa) - Trends, Analysis and Forecast till 2029”.

Key Highlights:

In August 2018, Alnylam Pharmaceuticals, Inc. received the U.S. Food and Drug Administration (FDA) approval for its ONPATTRO (patisiran) lipid complex injection— a RNA interference (RNAi) therapeutic— indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

In July 2018, Ionis Pharmaceuticals, Inc. and Akcea Therapeutics, Inc. received marketing authorization approval for its drug TEGSEDI (inotersen) from the European Commission (EC) for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis.

Analyst View:

Increasing prevalence of transthyretin amyloidosis

The global transthyretin amyloidosis treatment market is likely to be driven by an increase in the prevalence of disease, rise in the population with African origin, increase in awareness, improvement in diagnostic procedures, improving health care services, rapid economic growth in developing countries, and rise in research and development activity. For instance, According to the Amyloidosis Foundation, there are roughly 126 different genetic variations in ATTR, with up to 53 types of genetic variations in non-transthyretin hereditary amyloidosis diseases. According to reports published on transthyretin amyloidosis, it has been estimated that nearly 10,000, or 1.1 per 100,000 individuals in the world are living with TTR-FAP. The age group of patients suffering from the disorder is between 30 and 40 years of age. It has also been observed that TTR-CM tends to affect older males aged 65 years and above. Familial amyloid polyneuropathy (TTR-FAP) leads to 100 different types of mutations in the transthyretin gene, which leads to protein misfolding. There is only a 50% chance of transferring the mutation to the next generation from an affected parent. On the other hand, the mutation that leads to familial amyloid cardiomyopathy is generally found in individuals of African origin. Amyloidosis related to age primarily affects Caucasian men who are aged 65 years and above.

Increasing healthcare awareness among people

The global ATTR market is likely to exhibit a robust growth during the forecast period due to the probability of rising number of ATTR therapeutic drugs launches, increasing African-American population as they are genetically susceptible to amyloidosis, increasing healthcare awareness among people, and rising average income of individuals. However, the growth of this market can be hindered by stringent regulatory policies, the high cost of ATTR drugs, and incorrect diagnosis of ATTR disorders and limitations of clinical trials. Lack of knowledge about this condition and unavailability of advanced diagnostic methods in the middle-income countries are the major challenges to the market.

Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “Global Transthyretin Amyloidosis Treatment Market”, By Drug (Inostersen, Partisiran, Tafamidis, and Others), By Indication (Wild Type ATTR Amyloidosis, and Hereditary ATTR Amyloidosis), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy), and By Region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa) - Trends, Analysis and Forecast till 2029

Key Market Insights from the report:        

The global transthyretin amyloidosis treatment market accounted for US$ 40.5 million in 2019 and is anticipated to register a CAGR of 58.7%. The market report has been segmented on the basis of drug, indication, distribution channel, and region.

Depending upon indication, the hereditary ATTR amyloidosis segment is projected to grow at highest CAGR over the forecast period. The hATTR is caused by the misfolding of protein monomers resulting from the TTR.

Depending upon distribution channel, the hospital pharmacy segment is projected to grow at highest CAGR over the forecast period

By region, North Americas dominates the market for Transthyretin (TTR) amyloidosis owing to the increasing prevalence of amyloidosis among adults and older population and rising geriatric population which is a major trigger factor for this disease. The presence of pharmaceutical giants such as Pfizer, Merck, etc. also propels the market growth in this region.

[sapanas]

Transthyretin (TTR) Amyloidosis Market Growth To Surge Owing To Increasing Adoption By End-Use Applications

Market Research Future has declared the expansion of the "Worldwide Transthyretin (TTR) Amyloidosis Market Research Report which gives Market Size, Shares and Forecasts till 2023.

Transthyretin (TTR) Amyloidosis Market Analysis

Market Research Future (MRFR) report on the global transthyretin (TTR) amyloidosis market (2018-2023) analyzes COVID-19 on the main factors that drive market growth. The study addresses competitors in the market and global market trends, offering a detailed summary of both growth factors and constraints, which may have a direct or indirect effect on the outlook of the industry during the forecast period.

Transthyretin (TTR) amyloidosis is a medical disorder characterized by the build-up of irregular protein deposits called amyloid (amyloidosis) in the body's organs and tissues. It primarily affects the peripheral neuropathic or autonomic neuropathic system and the cardiac system. The cardiac type of transthyretin (TTR) amyloidosis puts patients at risk of arrhythmia, cardiomegaly, and orthostatic hypertension.

Read more news on: https://www.medgadget.com/2020/07/covid-19-pandemic-impact-on-transthyretin-ttr-amyloidosis-market-2020-global-industry-size-share-business-opportunities-new-advancement-strategies-sales-revenue-regional-statistics.html

Transthyretin (TTR) Amyloidosis Market Key Players

Some of the key players identified by MRFR in this market are Alnylam Pharmaceuticals, Pfizer, Merck, Arcturus Therapeutics, Ionis Pharmaceuticals Inc., Corino Therapeutics Inc, Proclara Bioscience.

Transthyretin (TTR) Amyloidosis Market Dynamics

The global ATTR market is expected to show robust growth during the forecast period due to the probability of an increase in the number of ATTR drug launches, an increase in the Afro-American population as they are genetically susceptible to amyloidosis, an increase in people's health awareness and the average income of individuals.

Nevertheless, the growth of this market can be hampered by strict regulatory policies, the high cost of ATTR drugs, the inaccurate diagnosis of ATTR disorders, and clinical trials' limitations. Lack of information on this condition and inadequacy of advanced diagnostic methods in middle-income countries are significant market barriers.

Transthyretin (TTR) Amyloidosis Market Segmentation

The global transthyretin (TTR) amyloidosis market has been segmented based on disease type, treatment, gender, and end-user.

Based on the type of disease, the global market for transthyretin (TTR) amyloidosis has been segmented into transthyretin (TTR) familial amyloid cardiomyopathy, transthyretin (TTR) familial amyloid polyneuropathy, and others.

Based on treatment, the global market for transthyretin (TTR) amyloidosis has been segmented into small molecules treatment, organ transplantation, RNAi therapy and others. The segment for small molecules treatment is further divided into tafamidis and diflunisal.

Based on gender, the global market for transthyretin (TTR) amyloidosis has been segmented into males and females.

Based on the end-user, the global market for transthyretin (TTR) amyloidosis has been segmented into hospitals and clinics, ambulatory surgical centers, and others.

Transthyretin (TTR) Amyloidosis Market Regional Analysis

By region, the global market for transthyretin (TTR) amyloidosis has been segmented into the Americas, Europe, Asia Pacific, and the Middle East and Africa.

The Americas leads the market for transthyretin amyloidosis (TTR) due to a growing prevalence of amyloidosis among adults and the elderly and a rising geriatric population, which is a significant cause for this disease. For example, according to a study released by ASCO Journal in 2016, approximately 4,000 people develop amyloidosis per year in the United States. As a result, this growing patient pool will fuel demand growth during the forecast period. In addition, factors such as increasing government initiatives and support for research, the advancement of advanced medical treatment options, and the growing usage of technologically advanced medical diagnostic devices are likely to propel the market. The presence of pharmaceutical giants such as Pfizer, Merck, etc. is also driving market growth in this region.

Europe is the second-largest market and has a fair share of the overall market for transthyretin (TTR) amyloidosis. The European market is expected to show significant growth during the forecast period due to main factors such as the availability of advanced treatment facilities, increased spending on healthcare, as well as an increasing need for better healthcare infrastructure, and government initiatives to reform health care. Approximately 60 new cases of transthyretin (TTR) amyloidosis are recorded annually in the United Kingdom, and the age-specific incidence rate is between 5.1 and 12.8 per million per year. In addition, the growing demand for medical devices and the capability of people to afford diagnostics contribute to the industry's growth. However, the inefficiency of treatment and the incorrect diagnosis is hindering the growth of the market in this area.

The Asia Pacific is anticipated to be the fastest-growing region. According to a study published by the United Nations in 2015, the number of older adults aged 60 years or older in the world is expected to rise by 56% between 2015 and 2030, of which 66% of the elderly reside in the Asia Pacific region. It makes the region vulnerable to transthyretin (TTR) amyloidosis as the chances of its occurrence increase with rising age. Due to a broad patient population, rapid adoption of healthcare technologies, government initiatives to enhance healthcare quality, and availability of favorable reimbursement and insurance policies, market growth will accelerate throughout the forecast period. In addition, major players such as Pfizer, Merck, etc. have developed their regional headquarters and manufacturing facilities in countries like Singapore, China, Japan, Korea, and Australia. As a result, the growth curve of the in transthyretin (TTR) amyloidosis market will show a positive growth pattern.

The Middle East and Africa are anticipated to exhibit the lowest growth in the market due to some key factors such as dearth of awareness and limited access and availability of treatment facilities. In the Middle East, Saudi Arabia and the United Arab Emirates are the major markets due to the development of the healthcare sector and the increasing availability of specialized care centers. However, the market may show steady growth due to the genetic vulnerability of Africans to transthyretin amyloidosis and government initiatives to augment the quality of healthcare in the region.

Obtain Premium Research Report Details, Considering the impact of COVID-19 @ https://www.marketresearchfuture.com/reports/transthyretin-amyloidosis-market-6155

[severetacoartisan]

“Transthyretin Amyloidosis (ATTR) Market” report provides a detailed analysis of global market size, regional and country-level market size, segmentation, market growth, market share, and competitive landscape.

[fortunatelyfuturisticmentality]

Transthyretin Amyloidosis Treatment Market Slated US$ 1,077 Mn by 2028| Prothena Corporation, Pfizer, Ionis Pharmaceuticals, Valeant, Celgene, Takeda, Johnson and Johnson, AstraZeneca, GlaxoSmithKline

Transthyretin Amyloidosis Treatment Market expecting for US$ 1,077.7 million, anticipated to register a CAGR of +58% by the term plan of 2021-28.

TTR amyloidosis is a specific type of amyloidosis that is very rare. TTR stands for transthyretin, a protein that is primarily made in the liver. TTR amyloidosis occurs when this protein “misfolds” or changes its shape in an abnormal way, and forms into fibrous clumps.

TTR amyloidosis is a systemic disease in which amyloid deposits can be visualized in most tissues such as skin, fat pad, rectal mu- cosa, gastric mucosa, nerve tissue or, myocardium. Tissue biopsy should be performed, ideally of an affected organ.

Liver transplantation removes the source of mutated TTR molecules and prolongs survival, with a 20-year survival of 55%.

On average, people with familial ATTR amyloidosis live for 7 to 12 years after they get their diagnosis, according to the Genetic and Rare Diseases Information Center. A study published in the journal Circulation found that people with wild-type ATTR amyloidosis live an average of about 4 years after diagnosis.

Request for a sample report here @ https://www.reportconsultant.com/request_sample.php?id=80362

Major Players Covered in this Report:

Prothena Corporation plc., Pfizer Inc., Ionis Pharmaceuticals Inc., Valeant Pharmaceuticals International Inc., Celgene Corporation, Takeda Pharmaceutical Company Ltd., Johnson and Johnson Pvt. Ltd., GlaxoSmithKline plc, Alnylam Pharmaceuticals Inc., SOM Innovation Biotech S.L., AstraZeneca plc.

Report Consultant announced latest research on growth factors and development of Global Transthyretin Amyloidosis Treatment Market. A detailed study accumulated to offer latest insights about acute features of the Transthyretin Amyloidosis Treatment market. The report contains different market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market. It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary and SWOT analysis.

Transthyretin Amyloidosis Treatment Market Study assures you to advise higher than your competition. With Structured tables and figures examining the Transthyretin Amyloidosis Treatment, the research document provides you a leading product, submarkets, revenue size and forecast to 2028.

The study report offers a comprehensive analysis of Transthyretin Amyloidosis Treatment market size across the globe as regional and country level market size analysis, CAGR estimation of market growth during the forecast period, revenue, key drivers, competitive background and sales analysis of the payers. Along with that, the report explains the major challenges and risks to face in the forecast period.

Market segmentation by drug:

Inostersen

Partisiran

Tafamidis

Others

Market segmentation by Indication:

Wild Type ATTR Amyloidosis

Hereditary ATTR Amyloidosis

Market segmentation by Distribution Channel:

Retail Pharmacy

Hospital Pharmacy

Online Pharmacy

Market segmentation by regions:

North America

Europe

Asia-Pacific

Middle East and Africa

Rest of the world

The research report of the Transthyretin Amyloidosis Treatment market offers broad analysis about the industry on the basis of different key segments. Moreover, the research report presents a comprehensive analysis about the opportunities, new products, and technological innovations in the market for the players.

Additionally, the research report on Transthyretin Amyloidosis Treatment market provides an in depth analysis about market status, market size, revenue share, industry development trends, products’ advantages and disadvantages of the enterprise, enterprise competition pattern, industrial policy and regional industrial layout characteristics. Thus the study report offers a comprehensive analysis of market size across the globe as regional and country level market size analysis, estimation of market growth during the forecast period.

Get upto 40% Discount available on this Report @ https://www.reportconsultant.com/ask_for_discount.php?id=80362

This study also covers company profiling, specifications and product picture, sales, market share and contact information of various regional, international and local vendors of Global Transthyretin Amyloidosis Treatment Market. The market opposition is frequently developing greater with the rise in scientific innovation and M&A activities in the industry. Additionally, many local and regional vendors are offering specific application products for varied end-users. The new merchant applicants in the market are finding it hard to compete with the international vendors based on reliability, quality and modernism in technology.

Detailed TOC of Transthyretin Amyloidosis Treatment Market Research Report-

– Transthyretin Amyloidosis Treatment Introduction and Market Overview

– Transthyretin Amyloidosis Treatment Market, by Application

– Transthyretin Amyloidosis Treatment Industry Chain Analysis

– Transthyretin Amyloidosis Treatment Market, by Type

– Industry Manufacture, Consumption, Export, Import by Regions

– Industry Value ($) by Region

– Transthyretin Amyloidosis Treatment Market Status and SWOT Analysis by Regions

– Major Region of Transthyretin Amyloidosis Treatment Market

i) Global Transthyretin Amyloidosis Treatment Sales

ii) Global Transthyretin Amyloidosis Treatment Revenue & market share

– Major Companies List

– Conclusion

[latestanalysis]

Europe Genetic Testing Market Top 5 Competitors, Regional Trend, Application, Marketing Strategy, Outlook Analysis and Forecast

Europe Genetic Testing market was valued at US$ 2,472.0 Mn in 2020 and it is projected to reach at US$ 4,262.4 Mn by 2027, at a CAGR of 8.5% during the forecast period. Major factors accounting for this growth include the increase in incidences of genetic, infectious & chronic diseases, reduction in prices of genetic sequencing, rising adoption of precision medicine diagnostic techniques. Genetic testing is defined as medical test which detect changes in proteins, genes or chromosomes. The test results are able to confirm a speculated underlying genetic condition or aid in determining an individual’s chance of developing/ passing on a genetic disorder.

Market Drivers: Increasing focus of government for genetic testing awareness

The growing focus by governments of several countries, to regulate& create awareness regarding genetic tests, has successfully resulted in the faster adoption of these tests worldwide. The rise in Research & Development funding, with the strong market presence by major players in the market, has created a strong entry barrier for new entrants. The increasing innovation in product design, improvement in quality, and strong distribution partnerships are key factors to retain a competitive edge in the market.

Get Sample Copy of this Report @ https://qualiketresearch.com/request-sample/Europe-Genetic-Testing-Market/request-sample

Rising demands for newborn and pre-natal screening to detect congenital abnormalities, growing application of bio banking services that involve DNA testing as a crucial step for cord blood banking are further attributive for progress in this sector. Growing Physicians’ interest towards genetic testing in order to determine patient’s health at various stages of disease development is another factor anticipated to fuel demand in the coming years.

Factors such as increasing implementation of personalized medicine applications to treat chronic disorders enhancing the need for HLA typing & DNA identification for therapy are expected to further add to the growing demand for DNA diagnostics. Moreover, hi-tech advancements which result into commercialization of next generation diagnostic & testing solutions making use of genetic analysis are anticipated to positively impact on Europe genetic testing market growth.

Market Restraints: COVID-19 has negative impact on Europe genetic testing market

The COVID-19 pandemic has left a prominent impact on the growth of the genetic testing market over the crisis. As per the research article published in Genetics in Medicine (2020), all the clinical genetic testing was restricted & telemedicine-based consultations and counseling were adopted across the globe. According to this study, 112 prenatal & 156 clinical genetics/cancer patients were evaluated in a span of one month at the Columbia University Irving Medical Center (CUIMC).

Most of the genetic testing services are adopted virtualization, coupled with home testing kit or home sample collection, to combat the transmission of the SARS-CoV2 virus. Moreover, as per the research article published in the Journal of Medical Genetics (2020), there was hindrance reported in accessing genetic testing blood draws, as a result of that the genetic testing was prominently impacted, wherein a reduction in genetic testing from 97.7% to 74.1% was observed during this period. Hence, COVID-19 is anticipated to have a direct & indirect impact on the genetic testing market over the ongoing crisis period.

Europe Genetic Testing Market Share Analysis by Technology

Based on Technology, the Europe genetic testing market is categorized intoCytogenetics Testing, Biochemical Testing and Molecular Testing.

Cytogenetic testing segment is the second highest revenue generating technology in Europe genetic testing market. The growth is attributed due to rise in healthcare expenditure that has resulted in the increasing use of cytogenetic products in clinical and research laboratories, academic research institutes, and pharmaceutical and biotechnology companies. Also, cytogenetic is used in the development of targeted cancer treatment, personal medicine, and others. Currently, a wide range of techniques such as comparative genomic hybridization, fluorescence, karyotyping, and others are employed for the screening of genetic abnormalities and cancers. These techniques employ the use of cytogenetic products including media, kits, reagents, and others. This factor is expected to drive the Cytogenetic testing segment over the forecast period.

Europe Genetic Testing Market Share Analysis by Type

Based on type segment, the Europe genetic testing market is categorized into Carrier Testing, Diagnostic Testing, Newborn Screening, Predictive & Presymptomatic Testing, Prenatal Testing and Others.

Diagnostic Testing has accounted for the highest market share in 2020. This is due to rising incidence of genetic and other chronic disorders. As per the information published on World Health Organization (WHO), the increase in prevalence of inherited diseases like sickle cell anemia, cystic fibrosis and hemophilia will contribute the overall market size for genetic tests. Additionally, early disease diagnosis further allows patients to undergo therapeutic treatment at an early stage that minimizes the severity of disease leading to reduced mortality rate and hence proving beneficial for the segment expansion.

Europe Genetic Testing Market Share Analysis by Disease

Based on Disease segment, the Europe genetic testing market is categorized into Alzheimer's Disease, Cancer, Cystic Fibrosis, Sickle Cell Anemia, Duchenne Muscular Dystrophy, Thalassemia, Huntington's Disease and Others.

Cancer disease has accounted for the highest market share in 2020. Genetic testing is very helpful to estimate the chances of developing cancer throughout an individual’s lifetime by examining for specific changes in chromosomes and genes, proteins. Cancer, globally, is the 2nd leading reason of death, and approximately70% of deaths from cancer occurs in low- and middle-income countries which raises the demand for genetic testing. As, significant enhancements can be made in the lives of cancer persons by diagnosing at an initial stage & avoiding postponements in care resulting in reduced morbidity, less expensive treatment & greater probability of surviving. This factor creases the demand for genetic testing for cancer.

Europe Genetic Testing Market Share Analysis by Country

Germany, The U.K., Italy and France are top country in Europe genetic testing market. These countries collectively accounted for more than 50% of market share in 2020. The presence of developed healthcare infrastructure, strong government initiatives and proactive funding for genetic testing research, and high prevalence of chronic diseases are the major drivers for industrial growth in these countries.

Other European countries is expected to create significant opportunity in genetic testing due to rising research incentives provided by the government in developing economies of this region that enable R&D and commercialization of technologically advanced products. Moreover, higher availability of target population owing to the incidence of chronic diseases in this region is also expected to supplement growth in the coming years.

Recent Developments:

In March 2020, Abbott had launched molecular point-of-care test to detect novel coronavirus in short time period, 5-15 minutes. The ID NOW platform is small, lightweight & portable (the size of a small toaster), and uses molecular technology, which is valued by clinicians and the scientific community for its high degree of accuracy. ID NOW is already the most widely available molecular point-of-care testing. The company has already shipped 150,000 PCR tests to its existing customers, for use on its m2000 Real-time in vitro diagnostic system.

In March 2021, Qiagen had unveiled its Cloud-based platform, QIAsphere, that helps laboratories & QIAstat-Dx users remotely monitor tests & instrument status around the clock. QIAstat-Dx connectivity with the platform will enable QIAGEN technical service to check customers instrument health in real time, simultaneously offering them a quick response to reduced systems downtime. QIAsphere connectivity is made possible by connecting a small connectivity hub, QIAsphere Base (Qbase), to QIAstat-Dx, as well as other platforms, in less time through LAN or Wi-Fi network of hospitals, retaining sensitive data of patients within the hospital network.

In December 2020, CENTOGENE and Alnylam Pharmaceuticals has launched a New Clinical Program Aimed at Revolutionizing the Diagnosis of Hereditary Transthyretin-Related Amyloidosis (“ATTRv”).

Market Segmentation

The Europe Genetic Testing Market is segmented into type such as Carrier Testing, Diagnostic Testing, Newborn Screening, Predictive & Presymptomatic Testing, Prenatal Testing, and Others. On the basis of Disease, market is segmented into Alzheimer's Disease, Cancer , Cystic Fibrosis, Sickle Cell Anemia, Duchenne Muscular Dystrophy, Thalassemia , Huntington's Disease, and Others. Further, market is segmented into technology such as Cytogenetic Testing, Biochemical Testing, and Molecular Testing.

Also, the Europe Genetic Testing Market is segmented into various countries such as Germany, UK, France, Turkey, Switzerland, Norway, Sweden, Spain, Italy, Denmark, Finland, Iceland, Poland, Luxembourg, Netherlands, and Belgium.

Market Key Players

Various key players are listed in this report such as Abbott Laboratories, Illumina Inc., Eurofins Scientific, Qiagen, Elitech Group, Thermo Fischer Scientific, Centogene AG, Blueprint Genetics, 23andMe Inc., F. Hoffmann-La Roche Ltd, etc.

Market Taxonomy

By Type

Carrier Testing

Diagnostic Testing

Newborn Screening

Predictive & Presymptomatic Testing

Prenatal Testing

Others

By Disease

Alzheimer's Disease

Cancer

Cystic Fibrosis

Sickle Cell Anemia

Duchenne Muscular Dystrophy

Thalassemia

Huntington's Disease

Others

By Technology

Cytogenetic Testing

Biochemical Testing

Molecular Testing

By Country

Germany

UK

France

Turkey

Switzerland

Norway

Sweden

Spain

Italy

Denmark

Finland

Iceland

Poland

Luxembourg

Netherlands

Belgium

Browse Full Research Report @ https://qualiketresearch.com/reports-details/Europe-Genetic-Testing-Market

About Us

QualiKet Research is a leading Market Research and Competitive Intelligence partner helping leaders across the world to develop robust strategy and stay ahead for evolution by providing actionable insights about ever changing market scenario, competition and customers. QualiKet Research is dedicated to enhancing the ability of faster decision making by providing timely and scalable intelligence. We use different intelligence tools to come up with evidence that showcases the threats and opportunities which helps our clients outperform their competition.

[adwaitcoherent]

By 2026, CNS Specific Antisense Oligonucleotide Market To Surpass US$ 6,843.0 Million - Coherent Market Insights

CNS Specific Antisense Oligonucleotide Market To exhibit a CAGR of 24.9% over the forecast period (2018 – 2026).

Request for Sample PDF Copy:

https://www.coherentmarketinsights.com/insight/request-pdf/2477

Description:

Antisense oligonucleotide plays a major role in modern healthcare, as it acts on the messenger RNA level before the protein is formed to inhibit expression of certain diseases-causing genes.

 The global CNS specific antisense oligonucleotide market size was valued at US$ 883.7 million in 2017, and is expected to exhibit a CAGR of 24.9% over the forecast period (2018 – 2026).

 Figure 1. Global CNS Specific Antisense Oligonucleotide Market Value (US$ Mn), by Region, 2017

     CNS Specific Antisense Oligonucleotide  | Coherent Market Insights

                                                                           Source: Coherent Market Insights Analysis (2019)

 Increasing prevalence of cancer is expected to propel growth of the CNS specific antisense oligonucleotide market

 CNS specific antisense oligonucleotide is used for treatment of neurodegenerative disorders and associated rare diseases. According to February 2017, report of National Center for Biotechnology Information (NCBI), an estimated the prevalence of Cerebral palsy ranges from 1.5 to more than 4 per 1,000 of children from age 10 to 14 years. The birth prevalence of Cerebral palsy is around 2 per 1,000 live births globally.

 Furthermore, launch of new products for rare disease associated with CNS disorders is propelling growth of the CNS specific antisense oligonucleotide market over the forecast period. For instance, in October 2018, Ionis Pharmaceuticals, Inc. and Akcea Therapeutics, Inc. received the U.S.  Food and Drug Administration (FDA) approval for its novel drug TEGSEDITM (inotersen) indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. In the same year, company received approval from Canadian Health authority for the novel drug TEGSEDITM (inotersen).

 However, high cost of treatment and risk of toxicity is expected to hinder the market growth. According to the Journal Molecular Therapy, in May 2017, Biogen priced Spinraza (nusinersen injection) at US$ 750,000 for the first year’s treatment (US$125,000 per injection) and US$350,000 per year.

 Figure 2. Global CNS Specific Antisense Oligonucleotide Market Share (%), by Drug, 2018 and 2026

CNS Specific Antisense Oligonucleotide  | Coherent Market Insights

                                                                    Source: Coherent Market Insights Analysis (2019)

 Government support for development and launch of antisense drugs in North America is expected to bolster the market growth

 North America holds the dominant position in the global CNS specific antisense oligonucleotide market, owing to strong government support for antisense drugs. For instance, in March 2018, GeneTx Biotherapeutics LLC’s, GTX-101 received the U.S. Food and Drug Administration’s (FDA) orphan-drug designation for GTX-101 for the treatment of Angelman syndrome. It is a rare neurogenetic disorder that affects around one in 15,000 people, according to the FDA statement.

 Increasing prevalence of Alzheimer disease in the region is also expected to boost the market growth. For instance, in August 2012, National Center for Biotechnology Information (NCBI) stated Alzheimer disease as the most frequent cause of dementia in Western societies and estimated around 5.5 million cases in the U.S. and the prevalence worldwide is estimated to be as high as 24 million.

 Moreover, rich product pipeline for treatment of neurodegenerative disorders is expected to drive the market growth. For instance, in October 2017, Ionis Pharmaceuticals, Inc., initiated a Phase 1/2 clinical study of IONIS-MAPTRx in patients with mild Alzheimer's disease. Biogen funded US$ 10 million milestone payment to Ionis Pharmaceuticals, Inc.

 Moreover, key players in the players are focused on receiving the U.S. Food and Drug Administration (FDA) approval for novel products to reduce the burden of CNS associated disorders. For instance, in September 2016, Sarepta Therapeutics received the U.S. Food and Drug Administration (FDA) approval for Exondys 51(eteplirsen) used for treatment of rare genetic disorder Duchenne muscular dystrophy.

 Key Players

 Major players operating in the global CNS specific antisense oligonucleotide market include Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Biogen Inc., Ionis Pharmaceuticals Inc., Wave Life Sciences Ltd., Stroke Therapeutic Inc., Dynacure, ProQR Therapeutics N.V., and Q-STATE BIOSCIENCES, INC.

About Us: Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We do offer wide range of services such as Industry analysis, Consulting services, Market Intelligence, Customized research services and much more. We have expertise in many fields such as healthcare, chemicals and materials, Automation, semiconductors, electronics, energy, food and beverage, packaging and many more. Visit our website to know more.

 Buy Report Here:

https://www.coherentmarketinsights.com/insight/buy-now/2477

Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave.  #3200  Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com

[sapanas]

Transthyretin (TTR) Amyloidosis Market Trends, Industry Forecast, Applications, Growth Drivers, Trends & Demands

Transthyretin (TTR) Amyloidosis Market  Research Report - Global Forecast till 2023, Published by Market Research Future. MRFR Provides Transthyretin (TTR) Amyloidosis Industry Updates, Size, Share, Growth, Competitive Landscape, Regional Outlook

Transthyretin (TTR) Amyloidosis Market Overview

The Transthyretin (TTR) amyloidosis market is likely to register a robust growth over the forecast period. Transthyretin (TTR) amyloidosis is a health condition characterized by anomalous deposits of a protein named amyloid (amyloidosis) in a person's tissues and organs. It usually affects autonomic neuropathy or peripheral neuropathic system and cardiac system. Amyloidosis symptoms are often ambiguous having similarity to symptoms caused by other conditions. The symptoms vary based on the location and type of the amyloid deposits. Primarily, three major types of transthyretin amyloidosis have been identified. The neuropathic type of transthyretin amyloidosis affects the autonomic and peripheral nervous systems, resulting in trouble controlling bodily functions and peripheral neuropathy. The leptomeningeal type of transthyretin amyloidosis mostly affects the central nervous system. The cardiac type of Transthyretin (TTR) amyloidosis puts patients at the risk of orthostatic hypertension, cardiomegaly, and arrhythmia.

Read more news on: https://www.medgadget.com/2020/07/covid-19-pandemic-impact-on-transthyretin-ttr-amyloidosis-market-2020-global-industry-size-share-business-opportunities-new-advancement-strategies-sales-revenue-regional-statistics.html

The surging African American population, increasing number of ATTR therapeutic drug launches, increasing average income of individuals, and growing healthcare awareness among people serves as key factors for driving the Transthyretin (TTR) amyloidosis market growth.

However, progress of the market can be restricted by strict governing policies, incorrect diagnosis of TTR ailments, restraints on clinical trials, and high cost of TTR drugs. Unavailability of advanced diagnostic methods in the middle-income nations and lack of knowledge about Transthyretin amyloidosis acts as major challenges to the market.

Transthyretin (TTR) Amyloidosis Market Segmentation

The worldwide Transthyretin (TTR) amyloidosis market has been segmented based on treatment, gender, end-user, and disease type. Based on treatment, the market has been segmented into organ transplantation, RNAi therapy, small molecules treatment, and others. Small molecules treatment has been sub-segmented as diflunisal and tafamidis. Based on gender, the market has been segmented into male and female. Based on end-user, the market has been segmented into ambulatory surgical centers, hospitals and clinics, and others. Based on disease type, the market has been segmented into Transthyretin (TTR) familial amyloid polyneuropathy, Transthyretin (TTR) familial amyloid cardiomyopathy, and others.

Transthyretin (TTR) Amyloidosis Market Regional Analysis

The Americas hold the largest market share for Transthyretin (TTR) amyloidosis. The growth is owing to the rising occurrence of amyloidosis among adults and older population and increasing elderly population. For instance, a report published by ASCO Journal in 2016 stated that almost 4,000 people suffered from amyloidosis each year in the United States. Additionally, increasing government funding, technologically advanced diagnostic equipment, and surging research initiatives in advanced medical treatment options are likely to drive the market. The existence of leading pharmaceutical brands such as Merck and Pfizer also boost the market in this region.

Europe represents the second largest share in the global Transthyretin (TTR) amyloidosis market. The Europe market has been anticipated to grow remarkably over the forecast period. The growth is owing to soaring healthcare expenditure, availability of progressive treatment facilities, amplifying demand for improved healthcare infrastructure collectively with government initiatives for healthcare reform. In the U.K., almost 60 new cases of Transthyretin (TTR) amyloidosis are reported every year. Furthermore, increased affordability coupled with well-established medical device manufacturers accelerate the market to a great extent. However, increasing incidences of wrong diagnosis and the inefficiency of treatment procedures are likely to restrict the growth in the Europe market.

Asia Pacific market has been fast expanding owing to rising aged population. Moreover, increasing patient pool, government initiatives to enhance the healthcare facility, availability of favorable insurance reimbursement policies, and a rapid adoption of advanced technology are likely to stimulate the Transthyretin (TTR) amyloidosis market.

The Middle East and Africa market has been anticipated to register least growth owing to limited access to treatment facilities and lack of health awareness. In the Middle East, Saudi Arabia and the United Arab Emirates are the largest markets. The market growth has been attributed to the easy accessibility of specialty care centers and growth of healthcare industry. However, the market is expected to witness steady development due to the genetical predisposition of Africans for transthyretin amyloidosis and administrative initiatives to excel the quality of healthcare in the region.

Transthyretin (TTR) Amyloidosis Market Key Players

The global Transthyretin (TTR) amyloidosis market has been dominated by key players such as Pfizer, Alnylam Pharmaceuticals, Ionis Pharmaceuticals Inc., Arcturus Therapeutics, Corino Therapeutics Inc, and Proclara Bioscience.

Obtain Premium Research Report Details, Considering the impact of COVID-19 @ https://www.marketresearchfuture.com/reports/transthyretin-amyloidosis-market-6155

[pharmaphorumuk]

Sanofi and Alnylam conclude research phase of RNAi alliance

Sanofi and Alnylam have agreed to conclude the research and option phase of their 2014 RNAi therapeutics alliance for developing drugs for rare genetic diseases.

“Our alliance with Alnylam has successfully brought one important medicine to patients with ATTR amyloidosis and it also has spawned a molecule that is in pivotal clinical trials for people with hemophilia,” said John Reed, global head of research and development at Sanofi. “As we wrap up this phase of our programme, we remain committed to advancing therapies for patients with rare diseases and rare blood disorders.”

The $700 million alliance gives Genzyme/Sanofi a 12% share of Alnylam, and access to its drug candidates. The company can opt in to rare genetic disease programmes for commercialisation in territories outside the United States, Canada, and Western Europe, and has one right to a global licence.

Last year the companies restructured the alliance, with Alnylam taking back global rights to develop and commercialise products for the treatment of ATTR amyloidosis, including patisiran and an earlier pipeline drug, ALN-TTRsc02.

Meanwhile Sanofi gained global rights to develop and commercialise fitusiran, an investigational RNAi therapeutic for the treatment of haemophilia and, potentially, other rare bleeding disorders.

As part of this agreement, Alnylam will advance an additional investigational asset in an undisclosed rare genetic disease through the end of IND-enabling studies. Sanofi will be responsible for any potential further development or commercialisation of such asset. If this product is approved, Alnylam will be eligible to receive tiered double-digit royalties on its global net sales.

Later in the year Sanofi opted out of a co-development and co-marketing deal for one of the potential therapies – lumasiran, for Primary Hyperoxaluria Type 1 (PH1).

The decision was likely down to doubts about the drug’s long-term market potential. Despite this, Alnylam announced it would rapidly advance lumasiran into a phase 3 pivotal study and commercialise it globally.  

The two companies said that today’s announcement does not affect the material collaboration terms for patisiran, vutrisiran (ALN-TTRsc02) and fitusiran.

Alnylam and Sanofi also announced that they have agreed to amend certain terms of the companies’ equity agreement, with Sanofi obtaining a release of its lock-up of Alnylam stock holdings, subject to certain trading restrictions, amongst other provisions.

Alnylam’s Onpattro (patisiran) became the first RNAi drug approved by the FDA last year, for the nerve damage caused by the rare disease hereditary transthyretin-mediated amyloidosis (hATTR) in adults.

But the drug saw a setback in the UK when it was rejected by NICE on cost effectiveness grounds.

The post Sanofi and Alnylam conclude research phase of RNAi alliance appeared first on Pharmaphorum.

from Pharmaphorum https://pharmaphorum.com/news/sanofi-and-alnylam-conclude-research-phase-of-rnai-alliance/

[healthcare00897]

CNS Specific Antisense Oligonucleotide Market - Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

Antisense oligonucleotide plays a major role in modern healthcare, as it acts on the messenger RNA level before the protein is formed to inhibit expression of certain diseases-causing genes.

The global CNS specific antisense oligonucleotide market size was valued at US$ 883.7 million in 2017, and is expected to exhibit a CAGR of 24.9% over the forecast period (2018 – 2026).

Increasing prevalence of cancer is expected to propel growth of the CNS specific antisense oligonucleotide market

CNS specific antisense oligonucleotide is used for treatment of neurodegenerative disorders and associated rare diseases. According to February 2017, report of National Center for Biotechnology Information (NCBI), an estimated the prevalence of Cerebral palsy ranges from 1.5 to more than 4 per 1,000 of children from age 10 to 14 years. The birth prevalence of Cerebral palsy is around 2 per 1,000 live births globally.

Market Dynamics:

Increasing prevalence of neurodegenerative disease is a major factor driving CNS specific antisense oligonucleotide market growth. According to fact sheet from Alzheimer Association, an estimated around 5.7 million Americans were diagnosed with Alzheimer's dementia in 2018. Moreover, rich product pipeline for the treatment of CNS disorders and rare diseases associated with it is expected to boost the market growth. For instance, in December 2018, Biogen and Ionis Pharmaceuticals product IONIS-SOD1Rx (BIIB067) cleared Phase 1 clinical trial and is expected to be launched by 2020.

launch of new products for rare disease associated with CNS disorders is propelling growth of the CNS specific antisense oligonucleotide market over the forecast period. For instance, in October 2018, Ionis Pharmaceuticals, Inc. and Akcea Therapeutics, Inc. received the U.S. Food and Drug Administration (FDA) approval for its novel drug TEGSEDITM (inotersen) indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. In the same year, company received approval from Canadian Health authority for the novel drug TEGSEDITM (inotersen).

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/2477

Detailed Segmentation:

Global CNS Specific Antisense Oligonucleotide Market, By Drug:

Approved

Patisiran

Nusinersen

Inotersen

Pipeline

IONIS-HTT Rx (RG6042)

Global CNS Specific Antisense Oligonucleotide Market, By Indication:

Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy

Spinal Muscular Atrophy

Huntington’s Disease

Global CNS Specific Antisense Oligonucleotide Market, By Distribution Channel:

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Global CNS Specific Antisense Oligonucleotide Market, By Geography:

North America

Europe

Asia Pacific

Latin America

Middle East

Africa

Key Players

Major players operating in the global CNS specific antisense oligonucleotide market include Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Biogen Inc., Ionis Pharmaceuticals Inc., Wave Life Sciences Ltd., Stroke Therapeutic Inc., Dynacure, ProQR Therapeutics N.V., and Q-STATE BIOSCIENCES, INC.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

[anjrawat]

hATTR Amyloidosis Market

Hereditary ATTR (hATTR) amyloidosis is the most common form of ATTR and also a very rare disease. Familial Amyloidosis Polyneuropathy (FAP) and Familial Amyloidosis cardiomyopathy (FAC) are the two common types of hATTR.

The Hereditary Transthyretin Amyloidosis (hATTR) Market size in the 7MM was estimated to be USD 306.9 Million in 2017 and is anticipated to grow further in the forecast period 2020-30 owing to recent approvals and pipeline therapies. Among the 7MM geographies, the United States accounted for the 54% share of the total hATTR market size.

The key pharma companies in the Hereditary transthyretin amyloidosis market includes Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Inc., Eidos Therapeutics, and many others.

For more details on Hereditary Transthyretin Amyloidosis (hATTR) Market, visit: https://www.delveinsight.com/blog/hattr-market-hereditary-transthyretin-amyloidosis-market/

[chetanare]

Transthyretin Amyloidosis (ATTR) Market Overview 2020-2024

Transthyretin Amyloidosis (ATTR) Market Overview 2020-2024

“Global Transthyretin Amyloidosis (ATTR) Market Report 2019 – Market Size, Share, Price, Trend and Forecast” the new research report adds in kandjmarketresearch.com research reports database. This Research Report spread across 102 Pages, with summarizing Top companies and supports with tables and figures.

The recent report titled “The Transthyretin Amyloidosis (ATTR) Market” and forecast to…

[market-insights-dbmr]

Global Amyloidosis Treatment Market 2019 Worldwide Robust Expansion by Top Key Manufactures, Overview, Size, Share, Trends, Segments, Demand and Forecast to 2026

Global amyloidosis treatment market is expected to grow at a substantial CAGR in the forecast period of 2019-2026. Emergence of drugs used to treat risk associated with amyloidosis and high demand of disease specific novel therapies are the key factors that fueling the market growth.

Few of the major competitors currently working in the global amyloidosis treatment market are Takeda Pharmaceutical Company Ltd, Arcturus Therapeutics, Inc, Neurimmune, Pfizer Inc, Alnylam Pharmaceuticals, Inc, Proclara Biosciences, Fortress Biotech, Prothena, Spectrum Pharmaceuticals, Inc, Ionis Pharmaceuticals, Inc, Johnson & Johnson Services, Inc, Celgene Corporation, Eidos Therapeutics, GlaxoSmithKline plc, Amgen Inc, Fresenius Kabi AG, and others.

Get Sample Copy Of This Report @  https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-amyloidosis-treatment-market

Key Developments in the Market:

In June 2019, Alnylam Pharmaceuticals, Inc received an approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for Onpattro (patisiran), RNAi therapeutic targeting transthyretin (TTR) for the treatment of hereditary ATTR amyloidosis with polyneuropathy. With this approval, represents major advances in the treatment of these patients through targeted mode of action.

In May 2019, Pfizer Inc, received an approval from the FDA for both Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis), an oral transthyretin stabilizers for the treatment of hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. The FDA approval of Vyndaqel and Vyndamax greatly enhance the company’s business portfolio in the therapeutic area of metabolic disorder.

Competitive Analysis:

Global amyloidosis treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global amyloidosis treatment market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Inquiry For Customize Report With Discount at : https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-amyloidosis-treatment-market

Contact: Data Bridge Market Research Tel: +1-888-387-2818 Email: Corporatesales@databridgemarketresearch.com